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Abstract: Regional chemotherapy was first used for lung cancer 30 years ago. Since then, new 
methods of drug delivery and pharmaceuticals have been investigated in vitro, and in animals 
and humans. An extensive review of drug delivery systems, pharmaceuticals, patient monitoring, 
methods of enhancing inhaled drug deposition, safety and efficacy, and also additional applica-
tions of inhaled chemotherapy and its advantages and disadvantages are presented. Regional 
chemotherapy to the lung parenchyma for lung cancer is feasible and efficient. Safety depends 
on the chemotherapy agent delivered to the lungs and is dose-dependent and time-dependent. 
Further evaluation is needed to provide data regarding early lung cancer stages, and whether 
regional chemotherapy can be used as neoadjuvant or adjuvant treatment. Finally, inhaled che-
motherapy could one day be administered at home with fewer systemic adverse effects.
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Introduction
Lung cancer is responsible for 23% of total cancer deaths.1 Cancer survival tends to 
be poorer due to an often advanced stage at diagnosis. Only a minority of patients 
are eligible for curative surgical treatment. Until now, although new biomarkers have 
been under development for early diagnosis of lung cancer, early detection of lung 
cancer has not been achieved. Nonsmall cell lung cancer is the most common type 
of lung cancer worldwide, and various clinical studies are currently assessing new 
chemotherapeutic combinations.2–4 Although targeted and tailored therapies have 
been introduced for patients according to individual biological tumor characteristics, 
overall survival rates have failed to demonstrate the expected progression-free s  urvival 
or overall survival.5,6 Moreover, acquired resistance to cytotoxic agents has been 
observed, mainly involving the apoptotic mechanism in nonsmall cell lung cancer cell 
lines.7 In small cell lung cancer, five-year survival remains less than 10%, despite use 
of various drug combinations.8,9 In addition, acquired resistance has been observed 
in small cell lung cancer.10 Therefore, novel therapies are in great demand. The drug 
concentration reached in solid tumors is a key parameter for successful treatment 
and, until now, drug concentration at the tumor site has been found to be low after 
systemic chemotherapy.11,12
Nevertheless, drugs already being used for systemic administration have been suc-
cessfully administered regionally in various types of cancer.13–23 The concept of local 
drug delivery is proposed as a method for delivering high drug concentrations to the 
target site while preventing exposure of vital organs to toxic drug concentrations in the 
systemic circulation. In this way, systemic side effects are minimized. The respiratory 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1551
REvIEW
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S29997International Journal of Nanomedicine 2012:7
system has a large surface area, thin alveolar   epithelium, rapid 
absorption, lack of first-pass metabolism, high bioavailability, 
and the capacity to absorb large quantities of drug, making it 
an optimal route of drug administration.24 Aerosol therapy has 
also been evaluated, and is being used for several other condi-
tions and purposes, such as diabetes mellitus, gene therapy, 
and vaccination.25–29 Regarding aerosol chemotherapy adminis-
tered for lung cancer, a number of drugs have been investigated 
in vitro, in animal models, and in human trials.30–64 Several 
aspects of this treatment modality have been addressed due to 
the necessity for trials to be conducted, but several parameters 
remain to be clarified and expanded. The areas of this treatment 
modality that need to be properly addressed are summarized 
under the headings: prompt inhalation device; lung airway 
microenvironment; appropriate molecule-chemotherapy 
  selection; deposition evaluation; protection measures; and 
disease evaluation. In the current review, these topics will 
be addressed based on the published literature, and all prior 
knowledge on the subject will be presented.
We performed an electronic search of the PubMed, Google 
Scholar, Medscape, and Scopus databases using combina-
tions of the following keywords: “aerolized chemotherapy”, 
“inhaled chemotherapy in lung cancer”, “nanoparticles”, 
“aerosol devices”, “encapsulation”, “inhaled doxorubicin”, 
“inhaled carboplatin”, “inhaled cisplatin”, “inhaled 
paclitaxel”, “inhaled docetaxel”, and “inhaled 5-fluororacil”. 
All types of articles (randomized controlled trials, clinical 
trials, observational cohort studies, review articles, case 
reports) were included. Selected references from identified 
articles were searched for further relevant papers.
Lung anatomy and 
microenvironment
Airway geometry and humidity
Human lungs have a large (.100 m2), thin (0.1–0.2 µm), 
and highly vascular epithelial surface area for absorption. 
 Progressive branching and narrowing of the airways encour-
ages impaction of particles. The lung has a relative humidity 
of approximately 99.5%. Drug particles are known to be 
hygroscopic and to grow or shrink in size in high humidity. 
The increase in particle size above the initial size should 
affect the amount of drug deposited and, particularly, distri-
bution of the aerosolized drug within the lung.65,66 Further 
drug absorption could occur via the lymphatic pathway.67,68
Bronchial circulation
The lungs receive the entire cardiac output and represent 
the most richly perfused organ in the body. However, only 
the alveolar region is supplied by the pulmonary circulation. 
Blood flow to the larger airways (trachea, bronchi) is via 
the systemic circulation, and these airways receive approxi-
mately 1% of cardiac output.69 The endobronchial circulation 
is recirculated to the peripheral airways and lung parenchyma 
via the bronchial veins and right atrium. Bronchial blood 
flow is augmented in diseases such as bronchiectasis, from 
1% to as much as 30% of cardiac output.24 Theoretically, 
inhaled drugs that are absorbed into the circulation from the 
tracheobronchial regions can be redistributed downstream 
and peripherally into otherwise poorly accessible areas of 
the lung, which may aid in drug effectiveness.70
Lung clearance mechanisms
Drug particles deposited in the conducting airways are largely 
removed by mucociliary clearance. The airway epithelial 
goblet cells and submucosal glands secrete mucus, forming 
a two-layer mucus blanket over the ciliated epithelium, ie, 
a low-viscosity sol layer covered by a high-viscosity gel 
layer. Insoluble particles are trapped in the gel layer and are 
moved toward the pharynx (and ultimately to the gastroin-
testinal tract) by the upward movement of mucus generated 
via metachronous beating of the cilia.
In the normal lung, the rate of mucus activity varies 
depending on the airway area and is determined by the 
number of ciliated cells and their beat frequency. For normal 
mucociliary clearance to occur, the airway epithelial cells 
and ciliary structure and activity must remain intact. Further, 
the depth and chemical composition of the sol layer should 
be optimal and, finally, the rheology of the mucus must also 
remain within the physiological range. Mucociliary clearance 
is impaired in lung diseases such as immotile cilia syndrome, 
bronchiectasis, cystic fibrosis, and asthma.71 Lipophilic 
molecules pass easily through the airway epithelium via pas-
sive transport. Hydrophilic molecules cross via extracellular 
pathways and exocytosis.72 Particles are absorbed from the 
submucosal region into the systemic circulation, bronchial 
circulation, or lymphatic system. Drugs deposited in the 
alveolar region may be phagocytosed and cleared by alveolar 
macrophages or absorbed into the pulmonary circulation. 
Alveolar macrophages are the predominant phagocytic cells 
for lung defense against inhaled microorganisms, particles, 
and other toxic agents. There are approximately five to seven 
alveolar macrophages per alveolus in the lungs of healthy 
nonsmokers.73 Macrophages phagocytose insoluble par-
ticles that are deposited in the alveolar region and are either 
cleared by the lymphatic system or moved into the ciliated 
airways along currents in alveolar fluid and then cleared via 
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the mucociliary escalator.74 This process can take weeks to 
months to complete.75 Moreover, enzymes are still present 
in the lungs, so particles can be enzymatically degraded 
intracellularly (from alveolar macrophages) and/or extracel-
lularly by membrane-associated proteases and peptidases 
(both epithelial and endothelial).76
Lung disease
Bronchoconstriction, inflammation, and airway narrowing 
alter lung deposition. Respiratory diseases, such as cystic 
fibrosis and bronchiectasis, change the architecture of the 
lung. Alterations in bifurcation angles, turbulent flow, and 
obstruction of the airways due to mucus accumulation 
modify the deposition and distribution patterns of aerosols. 
A decrease in the cross-sectional area of the lung caused by 
obstruction increases air velocities and turbulence in regions 
where the airflow is usually laminar. Airway obstruction 
diverts inspired air to unobstructed airways and, thus, remark-
ably little drug is deposited in obstructed areas. Often the 
obstructed areas are those that need to be reached in order 
to achieve the optimal therapeutic effect of a drug.71,77–80 
Inhaled insulin was investigated as to whether it could be 
administered during an exacerbation and how this situation 
altered the dosage. It was observed that the drug could be 
administered and was tolerated by patients, but close glucose 
monitoring was required because release of the drug into the 
systemic circulation was insufficiently controlled.29
Methods enhancing lung deposition
It has been confirmed by plethysmography that addition of 
5%–7% CO2 into the inhalation system enhances the depth 
of absorption and drug quantity inhaled in every breath by 
reducing the respiratory rate and increasing the tidal volume 
by 180%. The subject is forced to breathe slowly and deeply. 
Nevertheless, it has been observed that if the mixture is 
enriched with a concentration higher than 7%, adverse effects 
are observed, with sleepiness, confusion, and severe dizziness 
being the most common.81–83
Tumor size
Tumor size affects the distribution and deposition of the 
inhaled compound. In previously published studies, the 
mass median diameter was required to be #3–5 cm upon 
diagnosis, otherwise patients were excluded from tri-
als.29,40,52,53,84,85 Anticancer drugs penetrate normal tissues by 
both diffusion and convection,86 with the net flow of fluid 
from blood vessels balanced by resorption into the lymphatic 
circulation.   Nevertheless, tumors caused by unstructured 
  neoangiogenesis lack functional lymphatics,87,88 which 
can lead to increased levels of interstitial fluid pressure in 
tumors,89–91 which in turn reduces convection and inhibits 
distribution of macromolecules.92,93 It has been previously 
demonstrated that some physicochemical properties of drugs, 
ie, shape, charge, molecular weight, and aqueous solubility, 
determine the rate of diffusion through tissue.86 The penetra-
tion of a drug is also dependent on its deconstruction, which 
functions to remove free drug, thereby inhibiting further 
permeation.86   Water-soluble drugs distribute most readily in 
the extracellular matrix and thus diffuse efficiently around 
and between cells. In contrast, lipid-soluble drugs penetrate 
lipid membranes, and so can be transported through cells.
Physical properties of drug formulations
Physical properties that have a significant role on the particle 
size of the inhaled suspension are viscosity ionic strength, 
osmolarity, and pH. If the values for pH and osmolarity in 
particular are not in the normal range, bronchoconstriction, 
coughing, and irritation of the lung mucosa is induced.94,95
Drug delivery systems
Optimal particle size
The inhaled drug formulation should consist of a specific 
particle size, in the range of 1–3 µm, to achieve substan-
tial alveolar deposition.24 Inhaled molecules of this size 
becomes trapped in the alveoli and taken up in vesicles by 
alveolar epithelial cells, so that they can be carried across 
and released on the opposite side in the narrow interstitial 
fluid compartment between the epithelial cells. Molecules 
are then taken up within vesicles by the endothelial cells, 
transported across the width of these cells, and released 
into the alveolar capillary bloodstream. This process of 
particle migration into, across, and out of a cell is known as 
t  ranscytosis. Other drug formulations given via inhalation, 
such as corticosteroids and anticholinergics, do not have to 
be less than 2–3 µm in size, because they act on the larger 
branches of the bronchial tubes.96
Pressurized metered dose inhalers
The pressurized metered dose inhalers (MDIs) use pro-
pellants, such as chlorofluorocarbons, which have been 
recently replaced by hydrofluoroalkanes.97 The aerosol is 
emitted through a nozzle at a high velocity of .30 msec). 
Nevertheless, only 10%–20% of the aerosol emitted from 
pressurized MDIs is deposited on the lung parenchyma.98 
The main reasons for this can be summarized as inspiratory 
flow rate and lack of hand-mouth coordination,99–101 and 
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the impact of high velocity particles and large particle size 
(50%–80%) on the oropharynx.102 In order to maximize the 
effectiveness of drug absorption from a pressurized MDI, 
the patient has to breathe slowly by decreasing respiratory 
frequency and increasing tidal volume. The inhaled volume 
is increased and the aerosol penetrates deeply into the lung 
parenchyma.103,104 To overcome the problem of actuation-
inhalation, coordination breath-actuated pressurized MDIs 
were introduced to the market.105 Nevertheless, improved 
peripheral deposition was observed if patients did not hold 
their breath on completion of inhalation in comparison with 
pressurized MDIs that are not breath-actuated.106 In addition, 
different spacer tubes, valved holding chambers, and mouth 
piece extensions were developed to reduce deposition in the 
oropharynx by decreasing particle size and slowing the veloc-
ity of the aerosol, and to produce a finer aerosol of smaller 
mass median aerodynamic diameter.107
Dry powder inhalers
Dry powder inhalers were designed to overcome poor 
actuation-inhalation coordination. There are two basic types 
on the market, ie, multidose (containing multiple doses) and 
single-dose capsule dry powder inhalers. Several differences 
in lung deposition have been observed between the various 
dry powder inhalers. Approximately 12%–40% of the emit-
ted dose is delivered to the lungs, and about 20%–25% is 
retained within the device.108–110 The reduced drug deposition 
has been attributed to inefficient disaggregation of ultrafine 
drug particles from coarser carrier lactose particles or drug 
pellets. Factors affecting disaggregation are high humidity, 
slow inhalation flow rate, and rapid and large deviations 
in temperature.111 Therefore, dry powder inhalers have to 
be stored in a cool, dry place. In addition, an exhalation 
maneuver is required before inhalation, because there is 
the possibility for a patient to exhale into the inhaler nozzle 
and disperse the dry powder. Pulmonary drug administra-
tion is enhanced for the dry powder inhalers because of fast 
inhalation.112 This occurs due to different internal resistance 
to airflow and a range differentiation from low to high 
resistance.113,114 Failure to use the device properly is a com-
mon error and therefore a dose is not delivered promptly.115 
Dry powder inhalers with high resistance provide increased 
deposition to the lung parenchyma,113,116 but the clinical 
significance of this remains to be clarified. Finally, recent 
developments, principally in overcoming forced inhalation 
effort, have produced active dry powder inhalers. This is 
achieved either by adding a battery-driven propeller that 
aids the dispersion of the powder or by using compressed 
air to aerosolize the powder and convert it to an aerosol in a 
holding chamber where its respiration is independent of the 
respiratory capability of the patient. Dry powder inhalers 
that are currently on the market are breath-actuated and still 
depend on the inhalation flow rate of the patient to achieve 
maximum drug dose inhalation.117
Nebulizers
Nebulizers have been used for many years to treat various 
respiratory diseases. They work by inhalation through a face 
mask, and can be used in respiratory distress by the elderly 
and children younger than 2 years of age. In addition, they 
can deliver large quantities of solutions and suspensions as 
small droplets with remarkably little patient coordination 
required. There are certain parameters of the aerolized solu-
tion affecting their efficiency, ie, pH, viscosity, ionic strength, 
osmolarity, and surface tension. High drug concentration, 
extremely low pH, and hyperosmolarity or hypo-osmolarity 
reduce drug output and provoke bronchoconstriction, cough-
ing, and irritation.94,95 Other additional significant factors 
can be summarized as the design of the nebulizer chamber, 
primary drug fill in the reservoir cup, tapping of the nebu-
lizer chamber during nebulization, time taken to nebulize 
a solution, gas flow and compressor characteristics, and 
residual volume.118 Until recently, there were two basic types 
of nebulizers, ie, jet nebulizers and ultrasonic nebulizers. 
Jet nebulizers take advantage of the energy provided by 
compressed gas flow and distribute the liquid substance in 
the reservoir cup into a fine mist. Jet nebulizers are widely 
used, but are rather inadequate (50% loss when continuously 
operated and only 10% deposited to the lungs) in comparison 
with the newer devices described below.119 Their performance 
is largely dependent on the compressor used.118,120 Newly 
introduced to the market are the breath-enhanced jet nebu-
lizers and the dosimetric nebulizers. The former delivers 
drug faster than the conventional jet nebulizers and the latter 
are breath-actuated, so generate aerosol only by inhalation. 
They are computer-controlled, and although they contrib-
ute by saving aerosol (up to 60%), they remain extremely 
expensive in comparison with conventional jet nebulizers.121 
The ultrasonic nebulizers use a piezoelectric crystal that 
vibrates at a high frequency (1–3 mHz) to produce a mist 
of liquid in the nebulizer. The higher the frequency used, the 
smaller the droplets produced. Ultrasonic nebulizers nebulize 
solutions faster than jet nebulizers, but are not suitable for 
suspensions. In addition, the piezoelectric crystal can heat 
and inactivate protein-based drugs.122 The latest nebulizers 
introduced onto the market are the vibrating mesh nebulizers, 
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which are divided either into active or passive systems. Their 
advantages over the previous systems are that they are very 
efficient, quiet, and portable, and have an extremely low 
residual volume to prevent drug waste. Moreover, some 
models provide feedback to the patient regarding dose 
delivery and patient adherence. Nevertheless, there are a 
number of disadvantages, in that they are expensive, and 
need maintenance and cleaning to prevent colonization by 
pathogens, buildup of deposits, and blockage of the aper-
tures. Finally, although vibrating mesh nebulizers are highly 
efficient overall, their performance varies according to the 
drug solution used and, therefore, licensing specific drugs 
with specific nebulizers is essential. This has no significant 
clinical importance when bronchodilators are delivered, 
given that they have a wide therapeutic index, but it is neces-
sary when delivering drug solutions containing liposomes 
or proteins.123–126 Facemasks are used for patients with 
acute respiratory distress and in uncooperative individuals. 
The facemask is not just a feature connecting the nebulizer 
to the patient, it also has to prevent face and ocular irrita-
tion.127–130 A mouthpiece is also used, and new mouthpiece 
designs are currently on the market which enable inhalation 
by breath actuation, incorporate drug-saving technology, 
and are environment friendly, protecting medical staff from 
having to dispose of unwanted solutions.29,30 Nevertheless, 
the mouthpiece is not indicated for acute respiratory distress 
conditions. Kleinstreuer et al84,131 have presented data regard-
ing the optimal combination of particle size, particle release 
position, and inhalation waveform that may deliver inhaled 
drug aerosols efficiently to the desired areas. Micron-sized 
particles follow trackable trajectories in human lung airways 
under steady laminar flow conditions. Therefore, the mouth 
inlet plays a crucial role, because it can affect the dispersion 
and deposition of the aerosol by backtracking.
Soft mist inhalers
Currently there is only one drug system of this kind available, 
which is a mechanical achievement of outstanding value. It 
uses the energy of a spring to force the solution through an 
extremely fine nozzle system.132,133 It produces a fine aerosol 
with relatively high lung deposition.134–136
Inhaled particle carriers  
and strategies
Liposomes
Liposomes have a variety of properties that can be sum-
marized as sustained release with reduced toxicity and 
less   irritation to the lung parenchyma, the possibility to 
manipulate release and targeting, and improved stability.137 
The amount of drug dose carried by the liposomes, and 
their release rate and deposition in the lung parenchyma 
depends on lipid composition, size, charge, drug/lipid ratio, 
and method of delivery.138–140 Liposomes are produced from 
phospholipids, which carry either no charge or a net negative/
positive charge.111,141 Their structure consists of an aqueous 
volume entrapped by a synthetic lipid single layer or bilayer 
with or without cholesterol. They are capable of encapsu-
lating either hydrophilic or lipophilic formulations.142,143 
However, formulations of intermediate solubility are poorly 
retained by liposomes, so they are manipulated to achieve 
a higher degree of retention.144 Liposomes are prepared for 
inhalation either in liquid or dry powder form.145 During 
nebulization, an amount of the formulation is lost and hence a 
manipulation of the lipid composition, and size and operating 
conditions are necessary to minimize the loss.146–149 The dry 
powder liposome formulations are produced by lyophilization 
followed by milling or by spray-drying.150,151 The sustained-
release capability of liposomes has been observed in several 
studies using a variety of drugs as aerosol treatment for the 
lung.29,50,152 To enhance the sustained-release properties 
of liposomes further, a polymer surface coating, such as 
polyethylene glycol (PEG), was developed. This addition, 
provided a “stealth” shield to the molecule to bypass the 
body’s defense mechanisms144,153,154 (Table 1).
Microparticles
Microparticles are produced from naturally occurring or 
synthetic polymers, and their size range is between 0.1 
and 500 µm. They are physically and chemically more 
stable than liposomes, so are capable of higher drug load-
ing. This property makes them an ideal carrier system for 
proteins and peptides.155,156 In order to encapsulate a drug, 
a number of factors, including heat, pH, oxygen, solvents, 
moisture, and mechanical stresses, must be assessed. 
Preparation for aerosol delivery can be undertaken using 
spray-drying, emulsion-solvent evaporation, phase separa-
tion, emulsion-solvent diffusion, and supercritical fluid 
technology.157–163 Moreover, manipulation of the following 
parameters will determine drug release: concentration, 
size, solubility, nature of micromolecular drug, molecular 
weight, porosity, tortuosity, and uniformity of the polymer. 
A coating is added to improve the time release character-
istics further, and 1,2-dipalmitoylphosphatidylcholine is 
also added to poly(DL-lactide-co-glycolide) microspheres 
to decrease uptake by macrophages.160 When chitosan and 
  hydroxypropylcellulose are added to the particles, their 
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particles,165 which have the ability to escape both phagocytic 
and mucociliary clearance in the respiratory system. They 
are prepared from nanoparticles, which eventually assemble 
into a microparticle of low density (,0.1 mg/mL). These 
particles need to be assessed with a drug load, but pub-
lished data suggest that they can be aerosolized from dry 
powder.157 It has been shown previously that a single cancer 
cell can ingest one or multiple microparticles. The ingested 
microparticles are arranged in such a way as to reduce the 
space occupied inside the cell, and the same occurs with 
macrophages44,167 (Table 1, Figure 1).
Carbohydrates
There are currently three carbohydrate formulations approved 
by the US Food and Drug Administration, ie, lactose (a-lactose 
monohydrate), glucose, and mannitol (polyol). These carri-
ers contribute to drug flow and dispersability, and also act as 
stability enhancers. In a recent study, several carriers such 
as mannitol, sorbitol, maltitol, and xylitol, were assessed 
and it was concluded that mannitol is the best candidate 
for dry powder inhaler formulation, given that the others 
showed limited dispersability.168 Techniques used to produce 
a respirable formulation are: supercritical fluid technology, 
spray-freeze drying, freeze-drying, and lyophilizing followed 
by milling/jet milling or spray-drying.169–173 Moreover, it has 
been observed that lactose enhances the uptake of polylysine 
into airway cells, and this has been shown to be a method of 
increasing intracellular localization of proteins and peptides.174 
Two approaches have been developed to improve delivery 
efficiency and increase drug dispersibility and the respirable 
fraction. The first approach was mixing fine lactose particles 
(about 5 µm in diameter) with coarse lactose to improve disag-
gregation, as well as the fine particle fraction.175 The second 
approach was to add a ternary component, such as L-leucine, 
Table 1 Efficiency enhancement mechanisms
Liposome composition (neutral or anionic lipids)
Phosphatidylcholines (lecithins)
Phosphatidylethanolamines Sphingomyelins
Phosphatidylserines
Phosphatidylglycerols
Phosphatidylinositols
Microparticles
Polylactic acid
Polylactic-co-glycolic acid
Sodium hyaluronate
Calcium phosphate-polyethylene glycol particles
Oligosaccharide derivatives
Oligosaccharide-lipid mix
Lipid-based Pulmosphere
Carbohydrates
Xylitol
Maltitol
Glucose
Sorbitol
Mannitol
Lactose
Cyclodextrins
Pegylation
Biodegradable polymers
Polylactic acid
Oligolactic acid
Mucoadhesive polymer
Bioadhesives
Lectins
Peptides
Antibodies
Heparin
Heparin sulfate
Octa-arginine
Antibodies
Cell-type specific targeting
Alveolar macrophages
Cancer cells
Epidermal growth factor
Folic acid
Low-density lipoprotein
Intracellular targeting
Intracellular trafficking
Endosomal release
Nuclear localization
time   residence in the lung parenchyma is increased.163 It 
has been widely agreed that the optimal geometric diam-
eter for lung delivery is 1–3 µm, but these particles tend to 
aggregate164 and are cleared by   alveolar macrophages.165 
Therefore, large porous particles were developed with a 
geometric diameter of .5 µm, an aerodiameter of ,5 µm, 
and a low density of ,0.1 mg/mL.166 When aerolized, large 
porous particles deposit homogeneously on the cell surface 
and, when observed by microscopy, appear nontoxic.161 
Further development of this molecule has led to “Trojan” 
MLV > 0.1 µm LUV > 0.1 mm
Interface-associated
drug
Hydrophilic drug
MLV = multilamelar vesicle
LUV = unilamelar vesicle
SUV = small unilamelar vesicle
LCL = long circulating liposome 
(with pegylation)
Hydrophobic drug
SUV LCL
Figure 1 Encapsulation vehicles.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1556
Zarogoulidis et alInternational Journal of Nanomedicine 2012:7
to the formulation.111 Finally, cyclodextrins, which are cyclic 
oligosaccharides, have proven to be useful excipients in the 
respiratory distribution of small molecules.176 Until recently, 
their use for protein/peptide delivery was limited due to the 
need to address penetration enhancement. However, in a 
recent study, the use of dimethyl-β-cyclodextrin presented 
increased bioavailability, with increasing concentrations of 
cyclodextrin169 (Table 1).
Pegylation
PEG added to proteins enables sustained release on the site 
of deposition. This is achieved by bypassing the defense 
mechanisms of the respiratory tract, by decreasing degrada-
tion of the formulation, and prolonging the half-life in the 
lungs.144,154,177 In addition, PEG has been demonstrated to be 
a safe carrier for inhalational agents178 (Table 1).
Biodegradable polymers
Polylactic acid has sustained release properties, but is not 
suitable for pulmonary drug delivery due to its prolonged 
biological half-life. An oligomer of lactic acid, with a shorter 
half-life (6–8 days), can be used for drug delivery. The 
mucoadhesive polymer, hydroxypropyl cellulose, is released 
over approximately 24 hours and bypasses mucociliary 
clearance. However, the toxicity profile of hydroxypropyl 
cellulose has not been established111,179 (Table 1).
Bioadhesives
Bioadhesives are used to prolong the connection between the 
carrier-drug and the surface cell in the airway.180,181 A num-
ber of multivalent binding agents have been incorporated in 
drug-carrier systems, including lectins, peptides, antibodies, 
octa-arginine, heparin, heparin sulfate, and antibodies182,183 
(Table 1).
Cell targeting
Cell targeting has been the focus of increasing interest 
in recent years, both from the prognostic and therapeutic 
points of view. Gene therapy has been widely investigated 
in cell-selective targeting.184 Alveolar macrophages are an 
attractive vehicle by which to deliver a chemotherapeutic 
agent to the lymph nodes through the lymphatic circulation. 
Liposomes and microspheres are generally engulfed by 
alveolar macrophages. Several receptors are overexpressed, 
such as epidermal growth factor and folic acid, which can 
be exploited to target specific cells in cancer therapy.185,186 
Low-density lipoprotein has been used for receptor assimila-
tion187 (Table 1).
Intracellular targeting
Intracellular targeting is an additional strategy to improve 
the efficiency of a drug. The general concept is to create a 
potent drug that would reach the proper surface area, but 
intracellular targeting is essential to take regional therapy a 
step further.188,189 In this regard, most chemotherapy regimens 
interact within the reproductive cell cycle, so this targeting 
strategy could be further pursued.190 There are three parameters 
that are investigated concerning the cell microenvironment 
and drug-formulation interactions, ie, intracellular trafficking, 
endosomal release, and nuclear localization (Table 1).
Drug transporters
ATP-binding cassette transporters
ABC transporters are a large family (50 members) of 
transmembrane proteins, which act as an ATP-dependent 
efflux system exporting molecules from the cytoplasm 
to the surrounding cellular environment. There are seven 
subfamilies, from A to G. ABC transporters prevent 
accumulation of xenobiotics, so they serve as a defense 
mechanism in lung tissue.191 P-glycoprotein, multidrug-
resistant proteins, and the breast cancer resistance protein are 
known to play a role in multidrug resistance, a characteristic 
observed during the expulsion of chemotherapeutic agents 
from cancer cells.192 P-glycoprotein has been extensively 
studied in the lung. It decreases oral drug absorption, 
prevents drug entry in the central nervous system, and 
is responsible for many drug-drug interactions.193 The 
transporter is localized based on immunohistochemistry 
techniques on the apical membrane of the bronchial and 
bronchiolar epithelium,194–197 in the endothelial cells of the 
bronchial capillaries,198 and in alveolar macrophages.195,196 
Expression of P-glycoprotein in smokers with lung disease 
versus people with normal lungs has not been adequately 
investigated. P-glycoprotein and immunohistochemical 
multidrug-resistant protein analyses are a useful tool for 
predicting a patient’s response to   chemotherapy.199 In 
one study, mRNA levels in the lung tissue of smokers, 
nonsmokers, and exsmokers were not found to be 
significantly different.194 Several studies have demonstrated 
directly or indirectly that underlying disease plays a role in 
regulation of the P-  glycoprotein transporter. In addition, 
pharmaceuticals administered for lung or other disease can 
upregulate the P-glycoprotein transporter. In cystic fibrosis, 
due to changes induced by the disease, it has been observed 
that the P-  glycoprotein t  ransporter is upregulated.200,201 
Moreover, it has been reported that   toxins released from 
microorganisms infecting patients with   cystic fibrosis also 
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inhibit P-glycoprotein.202 In patients with chronic obstructive 
pulmonary disease (COPD), there are no s  ignificant data 
indicating modification of P-  glycoprotein between the 
disease stages,203,204 and no relevant data exist for asthma 
patients. Corticosteroids administered by the inhaled, oral, 
and intraperitoneal routes upregulate the P-  glycoprotein 
transporter.205–207 A particularly good example of the 
i  mportance of transporters in inhaled chemotherapy is the 
inhibition of P-glycoprotein by lipid nanocapsules, which 
is a crucial mechanism of resistance for paclitaxel.208 There 
are nine multidrug proteins (MRPs). In normal lung tissue, 
MRP 1 and MRP 5 have been found to be highly expressed. 
MRP 6 and MRP 7 are moderately expressed, and MRPs 
2, 3, 4, 8, and 9 are either low or undetectable.209,210 MRP 
1 and MRP 2 are found in the bronchial and bronchiolar 
epithelium.195,211,212 MRP 1 is also found in alveolar 
macrophages.195,211 MRP 1 expression and levels are altered 
in patients with COPD.203,211 It has been previously shown that 
smoking downregulates the transporter, and the transporter 
has a protective role against cell damage.203,213 Ipratropium, 
N-acetylcysteine, and budesonide stimulate MRP 1 efflux 
and activity.214 Formoterol in combination with budesonide 
reduces transporter activity, but formoterol on its own does 
not have an effect on the transporter.214 In a study of inhaled 
doxorubicin, MRP 1 and MRP 2 were overexpressed.51 This 
information is crucial, because most lung cancer patients are 
also diagnosed with COPD. Breast cancer resistance proteins 
were first isolated from breast cancer cell lines. In a recent 
study, they were found to be highly expressed in human lung 
tissue using gene microarrays215 (Figure 2).
Organic cation transporters
Organic cation transporters belong to the greatest facilitator 
family and comprise five types of carriers, ie, electrogenic 
OCT 1, OCT 2, and OCT 3, and electroneutral OCTN 1 
and OCTN 2. OCT 1–3 are found in the trachea, smooth 
muscles of the airway, and ciliated bronchial cells, but there 
are contradictory data in terms of their expression. OCT 
N1 is expressed in the tracheal epithelium and alveolar 
macrophages, whereas OCT N2 is expressed in the alveo-
lar epithelium and airway epithelium.215–218 Published data 
for animal and in vitro cell lines implicate upregulation or 
downregulation of OCT transporters upon induced inflam-
mation or drug interactions related to asthma and/or COPD. 
Nevertheless, these are not clearly associated with a human 
model217–220 (Figure 2).
BCRP  Airway
OCT3  Epithelium
OCTN2
PEPT2
OCT1 Tracheal
OCT2 Epithelium
OCTN2
P-GP  Bronchial
MRP1 Epithelium
MRP2
OCT1
OCT2
PEPT1
P-gp    Alveolar
MRP1 Macrophages
OCTN1
P-gp     Alveolar
OCTN2 Epithelium
P-gp   Bronchiolar
MRP1 Epithelium
MRP2
P-gp  
MRP1-9
BCRP
OCTN1
OCTN2
PEPT1
PEPT2
OATP2B1
OATP3A1
OAT4A1
Trachea
Transporters
Figure 2 Transporters and their position where they are most highly expressed. 
Abbreviations: P-gp, P-glycoprotein; BCRP, breast cancer resistance protein; MRP, multidrug resistance-associated proteins; PEPT, peptide transporters; OCT, organic 
cation transporters; OCTN, organic cation transporters electroneutral; OAT, organic anion transporters; OATP, organic anion transporting proteins.
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Peptide transporters
Peptide transporters are part of the proton-coupled oligo-
peptide transporter group. The two main transporters are 
PEPT 1 and PEPT 2, which contribute to the high bioavail-
ability of peptide-like molecules. These peptides can affect 
the absorption and distribution of several inhaled antibiotic 
and antiviral drugs.221 PEPT 2 and more recently PEPT 1 
were detected first in the airway epithelium and then in the 
bronchial epithelium.222,223 These two transporters have also 
been found in animals and cell lines.224,225 However, how 
they interact with drug formulations and their activity in 
  respiratory diseases226 has not been fully investigated.
Organic anion transporters
There are six members identified, ie, OAT 1–4, URAT 1, 
and OAT 5, which are mostly found in the kidneys.227 Gene 
microarrays have confirmed their absence in human and 
murine lungs, but OAT 2 was highly expressed at these 
sites.215 In addition, OAT 4 mRNA was highly expressed in 
the bronchial cell lines Calu-3 and 16HBE14o-.224
Organic anion transporting polypeptides
There are 11 human organic anion transporting polypeptides 
(OATPs), which are divided into six families.228 Their actual 
tissue distribution has not been fully investigated.228 OATP 2B1,   
OATP 3A1, OATP 4C1, and OATP 4A1 expression has been 
found in human lungs, animals, and cell lines.215,224,229
Inhalation studies
There is a large amount of published data regarding aerosol 
delivery of chemotherapy in cancer cell cultures, animal mod-
els, and Phase I/II human studies (Table 2). These studies are 
best commented on in terms of the chemotherapeutic agent 
delivered to the lung parenchyma with additional individual 
parameters. The first chemotherapeutic agent, investigated 
almost 30 years ago, was 5-fluorouracil (5-FU).31 Tatsumura 
et al32 presented data for patients treated with inhaled 5-FU and 
underwent surgery immediately afterwards, who had higher 
drug concentrations in the tumor than in the surrounding tis-
sues. In addition, high 5-FU concentrations were found for up 
to 4 hours after administration in the main bronchus and in 
the lymph nodes around the main bronchus.32 This observa-
tion was confirmed in another study using 5-FU.60 Moreover, 
additional formulations of 5-FU with lipid-coated nanopar-
ticles or difluoromethylornithine, an important enzyme in cell 
proliferation, were devised to achieve sustained drug release 
and enhance anticancer properties.60,230,231 In these studies, pre-
viously presented for their inhalable system carriers with 5-FU, 
a step was made forward in using inhaled chemotherapy as an 
adjuvant treatment. Studies using taxanes either with liposome 
carriers, nanoparticles, polymeric micelles, or lipid nanocap-
sules provided evidence of an increased therapeutic index by 
prolonging regional action in the lung. Further, 5%–7% CO2 
has been used to enhance aerosolized drug deposition.50,82 
However, the data are controversial regarding the safety of 
taxanes at the lung parenchyma. The data indicate that the 
mononuclear   phagocyte system attacks the colloidal drug, so 
a combination of pegylated lipid nanocapsules is needed to 
prolong regional action. In addition, further studies will estab-
lish their efficacy in human subjects, after proper alterations/
additions to the drug formulation, such as nanoparticles232 or 
nanospheres,233 and when linked to human albumin.45,50,59,234,235 
Moreover, adverse effects, mainly neurotoxicity, was found to 
be dose-dependent, but also associated with increased tumor 
burden regression,50 and addition of cyclosporine A to the 
paclitaxel aerosol was found to enhance the anticancer effect 
of the treatment.55 It was observed that addition of cyclosporine 
A reversed the resistance of cancer cells to paclitaxel.55 When 
a taxane compound was compared with doxorubicin, it was 
noticed that adverse effects on the lung parenchyma were 
observed for the doxorubicin group, indicating that taxanes 
are safer in comparison with doxorubicin regarding the lung 
region.34 In addition, severe cardiotoxicity was seen in the 
doxorubicin group.34,47 Otterson et al37,52 created a protocol for 
inhaled chemotherapy in human subjects, covering all aspects 
of this treatment modality. Two Phase I and Phase I/II studies 
demonstrated the adverse effects of aerosol treatment, such as 
a metallic taste, mild bronchospasm, and moderate reduction 
of pulmonary function tests. Therefore, bronchodilators were 
administered before every session and patients rinsed their 
mouth with water afterwards. It was observed that a signifi-
cant drawback was the timing of administration of the drug 
formulation (60 minutes). Aerosol deposition was evaluated 
by radiolabeling, and remission of pulmonary function tests 
was observed after every chemotherapy session. In addition, 
other basic characteristics of this protocol proposal for inhala-
tion chemotherapy were addressed, such as inclusion criteria. 
It is essential to highlight tumor size, which must not be more 
than 5 cm in mass median diameter, because this parameter 
is crucial for drug deposition.84,131 These issues are analyzed 
further in the safety section. In another study using nanopar-
ticles with doxorubicin, it was observed that macrophages 
clear the formulation, so smaller nanoparticles need to be 
developed.47 Platinum analogs have also been investigated, 
and the findings were similar to those for inhaled doxorubicin. 
Moderate bronchospasm after aerosol inhalation, cough, fever 
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(three days in some cases), and a metallic taste were observed. 
Bronchodilators were administered before every session. 
Pulmonary function tests were also performed according to 
the American Thoracic Society/European Respiratory Society 
guidelines53,56,236,237 along with a high resolution CT scan of 
the thorax.30,53 Mild reduction in pulmonary function tests 
was observed immediately after the chemotherapy session, 
but regressed until the next cycle.
In a study by Tseng et al45 a biotinylated epidermal 
growth factor-modified gelatin nanoparticle carrier was 
investigated, and found to enhance the anticancer activity 
of the formulation. In addition, it paved the way for targeted 
inhaled chemotherapy. Cancer cells with epidermal growth 
factor overexpression show increased uptake of this 
formulation. An additional benefit is reduced nephrotoxicity, 
because more cisplatin remains regionally in the lung 
cancer cells, and fewer carriers with cisplatin are delivered 
to the systemic circulation. Anderson et al49 administered 
a novel nonhydrolyzable ether-linked acetic acid analog 
of vitamin E (a-TEA) with intraperitoneal administration of 
cisplatin. This treatment is mentioned due to the positive effect 
observed in reducing lung metastasis to the lungs.49,238,239 The 
a-TEA could be used as a molecule additional to the aerosol 
formulation, in order to augment apoptosis of cancer cells and 
to decrease cancer cell proliferation.49,57,239 Again, safety issues 
are discussed in the safety section. The anticancer effect of 
9-nitro-camptothecin as an aerosol has been established.56,57,240 
Several formulations using carrier systems have been 
used to deliver sustained-release 9-nitro-camptothecin. 
  Feasibility and effectiveness was established, and in addition 
to encapsulation with carriers, pegylation added a “stealth” 
property, as previously mentioned. The macrophages did not 
recognize the formulation and so did not attack, but cancer 
cells ingested the molecules due to the cationic charge (PEG 
technology).44 However, the polystyrene microparticles used 
in this study cannot be used in human subjects because they 
cannot be eliminated from the body. Therefore, an initiative 
to develop biocompatible aggregated nanogel particles has 
been started using additional PEG technology.44 In a study 
by Verschraegen et al56 aerosol therapy was taken to a level 
never previously achieved. After effectiveness and safety 
had been observed, patients were educated to receive their 
therapy at home. This study provides evidence that, if safety 
and effectiveness of such a system is confirmed, patients 
can receive any chemotherapy agent without having the side 
effects that are usually observed with these agents.
Gemcitabine, a well known chemotherapeutic agent, 
has been evaluated in dogs and baboons as an aerosol 
formulation. The formulation was radiolabeled and blood 
samples were collected until 360 minutes.43,241,242 The effi-
cacy of this treatment modality on lung metastasis due to 
osteosarcoma was investigated, along with Fas/FasL expres-
sion. The Fas ligand is a type II transmembrane protein that 
belongs to the tumor necrosis factor family. Fas expression 
in metastatic foci was increased compared with that in lung 
metastases before treatment, and at even higher levels than 
in the   primary tumor. The results of these studies indicate 
that aerosolized gemcitabine treatment is effective against 
metastatic osteosarcoma lesions.61 Gemcitabine has been 
administered to patients with lung cancer, either as an aero-
sol or instilled into the lung parenchyma, and the data have 
demonstrated efficacy.243,244 The safety of gemcitabine in 
humans is discussed in the safety section.
Safety and protection measures
Both patients and medical staff should be considered concern-
ing safety (Table 2). The question that needs to be answered 
is whether interstitial lung disease is induced due to inhalation 
chemotherapy. Several agents have been observed to induce 
this kind of damage after intravenous administration.245–251 On 
high resolution CT, a ground-glass pattern, linear opacities, 
interlobular or intralobular thickening, and alveolar shadows 
were observed. Different histopathological appearances 
are also observed. Determining the background of pulmo-
nary infiltrates in patients who develop pulmonary severe 
involvement while receiving chemotherapeutic agents can 
be problematic. There are several factors that could pro-
duce this type of appearance, including pulmonary edema, 
alveolar hemorrhage, involvement of background disease, 
and   radiation. Moreover, a confirmatory biopsy or bron-
choalveolar lavage is often not possible to undertake due to 
respiratory distress or severity of the underlying condition. 
Because several chemotherapeutic agents may induce inter-
stitial lung disease by intravenous administration, a through 
safety evaluation has had to be performed for the aerolized 
formulations. Regarding the safety of medical personnel, 
the aerolized studies were performed with certain protection 
measures, including special plastic cages for animals.49,57 
Other measures for protection were the design of the deliv-
ery system or method. In a number of studies, the drug was 
delivered through a special nose-only chamber51 and using 
an intracorporeal catheter.41 An evaluation of whether these 
systems had sufficient environment safety was performed in 
several cases and the measures were adequate.34
Evaluation of pulmonary toxicity was observed by 
post mortem histological examination and radiological 
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investigations, ie, x-ray, magnetic resonance image, biolu-
minescent image, and V/Q scan.41,43,47,51 The most severe side 
effects were cough, weight loss, neurotoxicity, cardiotoxicity, 
alveolar interstitial pattern (radiological findings), moderate 
fibrosis (histopathological findings), and death as a result 
of pulmonary edema.34,41,43,50,54 One death was reported in a 
Phase I study by Otterson et al52 after doxorubicin aerosol 
administration, but autopsy revealed focal hyaline   membrane 
deposition and obstructive pneumonia due to tumor bur-
den. Staphylococcus and Acinetobacter baumannii were 
isolated from blood cultures, two bacteria commonly found 
in intensive care units, where the patient had been hospital-
ized due to severe respiratory distress. Death was attributed 
to disease progression. Selting et al41 demonstrated clearly 
that when administered repeatedly to a specific part of the 
respiratory airway, platinum analogs moderate the fibrosis 
and an alveolar interstitial pattern occurs. Nevertheless, these 
findings are dose-associated and depend on the time interval 
of treatment. When bronchospasm occurred and there was a 
drop in pulmonary function tests, additional steroid treatment 
reversed these adverse effects.34,37,52 These lesions did not 
appear using liposomal paclitaxel in studies which included 
histopathological evaluation.55 In a study by Tseng et al45 less 
nephrotoxicity was observed with biotinylated epidermal 
growth factor-modified gelatin nanoparticle carriers with a 
platinum analog, in comparison with a free circulating plati-
num analog. Regarding human subjects, studies used either 
a mouthpiece30 or a facial mask42,53,56 under a high efficiency 
particulate air system; the drug formulation which escaped 
(if any) was evaluated, and no toxic effects were found. In 
one study, the drug delivery system and formulation were 
evaluated and found to be efficient and safe enough that the 
patients were instructed to administer the drug formulation 
at home.56 Methods of evaluating the pulmonary parenchyma 
and respiratory capacity in human subjects have included 
pulmonary function tests with forced expiratory volume in 
one second (FEV1), forced vital capacity, carbon monoxide 
diffusing capacity (DLCO), the 6-minute walking test, and 
high resolution CT or CT scan.30,37,52,53,56 The patients included 
in these studies did not have any known collagen disease in 
order to be certain whether interstitial disease findings, if 
observed, were due to the inhaled compound. The adverse 
effects most commonly observed were coughing, mild bron-
choconstriction, fever, nausea, pharyngitis, thickening of the 
bronchial wall (high resolution CT finding),53 focal hyaline 
membrane deposition (post mortem finding),52 and reduction 
in pulmonary function tests that responded to corticosteroids 
or resolved after termination of treatment.30,37,53 In a study 
Table 3 Summary of inhaled chemotherapy in lung cancer
•    Although there is a variety of inhalation devices available on the 
market, each one with advantages and disadvantages, administration 
of an inhaled chemotherapy formulation is currently feasible through a 
nebulization system.
•    The aerosol compound time release can be enhanced by either adding 
a carrier which provides sustain release, or by adding 5%–7% CO2 to 
the inhalable aerosol.
•    Aerosol chemotherapy studies previously published provide 
conclusions with safety and feasibility of this treatment modality. 
Nevertheless, more trials are needed with patients of early stages 
to present long term data regarding adverse effects to the lung 
parenchyma. In addition, more single-agent or double-agent trials for 
the aerosol are needed to present indisputable data regarding the 
safety and effectiveness of this treatment modality in comparison with 
intravenous administration.
•    A question remains whether this treatment modality is proper for 
early lung cancer stages or as neoadjuvant/adjuvant, since tumor size 
is a limitation for patients to be candidates.
•    A new methodology of manipulating the aerosol deposition site 
according to cancer lesions has been proposed and developed, but is 
still under investigation.
•    Inhaled chemotherapy has been evaluated in a number of studies (high 
efficiency particulate air system) and the results indicate that certain 
drug administration systems are efficient enough to eliminate diffuse/
spilling of the aerosolized agent to the environment. The next step 
of aerosol chemotherapy agent administered inhouse has also been 
tested successfully with proper education and use by patients.
•    Administration of inhaled bronchodilators, corticosteroids, and 
N-acetylcysteine could prevent and protect the lung parenchyma from 
adverse effects.
•    The crucial question of whether such a treatment modality should be 
pursued will remain unanswered if further studies are not performed. 
The concept of a treatment modality for cancer patients free of 
systemic side effects is very tempting.
•    This treatment modality in order to have widespread acceptance, 
solid data regarding the safety and feasibility needs to be pursued.
by Garbuzenko et al51 alveolar hemorrhage and bronchial 
accumulation of chronic inflammatory cells were observed 
in histopathological specimens after aerosol administration 
of liposomal doxorubicin. Moreover, large bronchi were 
surrounded by aggregates of chronic inflammatory cells, 
including lymphocytes, macrophages, and plasma cells.51 In 
three studies, a mild reduction of FEV1, forced vital capacity, 
and DLCO was observed after aerosol administration and 
therefore bronchodilators and inhaled corticosteroids were 
administered before every treatment.30,37,52,53 Gemcitabine in 
an aerosol formulation did not induce fibrotic lesions in the 
lung parenchyma and does not contain any chemical ingre-
dients incompatible with aerosol delivery.43,62 Nevertheless, 
in an animal model, death from pulmonary edema occurred 
after aerosol administration of gemcitabine.43 Studies with 
9-nitro-20(S)-camptothecin did not report fibrotic lesions 
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in the lung parenchyma, although a reversible reduction in 
pulmonary function tests and mild adverse effects from the 
aerosol compound were observed (bronchial irritation, sore 
throat, pharyngitis).56 In studies performed in cancer cell 
lines, administration of the aerosol was conducted inside 
hoods, so medical personnel were safe from the toxic com-
pounds. Assessment of efficacy was made by observing the 
decrease in the population of cancer cells.58,59
Conclusion
Inhaled chemotherapy is a feasible treatment modality. 
Nevertheless, the pulmonary side effects of this treatment 
have to be assessed further. Until now, inhaled chemotherapy 
was administered for advanced lung cancer and, therefore, 
although some chemotherapeutic agents provided immediate 
evidence of dose/time-related toxicity, others did not due to 
the limited duration of administration. Early-stage lung can-
cer studies did not administer inhaled chemotherapy for more 
than one session.31,32 Therefore, studies involving early-stage 
lung cancer are needed to provide time/dose-related safety 
data. Moreover, studies providing doublet inhaled chemo-
therapeutic agents need to be performed because doublet 
chemotherapy is the cornerstone of treatment for lung cancer. 
However, these trials should not be performed until sufficient 
data regarding the safety profile in the lung parenchyma are 
available. Regarding efficacy, regional studies have dem-
onstrated positive results, but there are limitations to use of 
drug locoregionally according to tumor size, penetration of 
the drug at the tumor site, the chemical characteristics of the 
drug, and its biological effects. Regional therapy does not 
necessarily mean that higher drug levels reach the tumor. 
However, this concept contradicts the fact that, due to blood 
circulation in the lung52,53 and the lymphatic circulation, drug 
concentrations have been found in the systemic circulation 
and surgically resected lymph nodes.31,32,84,131,230,231,238 In addi-
tion, a high percentage of lymph nodes in the aerosol treat-
ment groups did not show any metastasis in several studies, 
so it is possible that this route of administration destroys 
tumor cells and prevents them from trafficking from the 
primary subcutaneous tumor to the lungs and lymph nodes 
via the lymphatic system.31,32,49,57 Nevertheless, in many 
of these studies, an additional intravenous chemotherapy 
regimen was administered, so clear conclusions cannot be 
drawn. Nanoparticles have the ability to evade macrophages 
and transport them into lung tissues other than the alveolus 
and into the general circulation.47 However, macrophages 
are a defense mechanism that is also responsible for clear-
ing the nanoparticles and, thus, reduce the anticancer effect 
of inhaled chemotherapy. Furthermore, an evaluation has 
to be made of whether inhaled chemotherapy is appropriate 
for early-stage lung cancer, or as neoadjuvant or adjuvant 
treatment.57,60,61,230,231
Because lesions are of smaller size, drug deposition is 
not prevented by the large mass median diameter of the 
tumor.131 Current drug delivery systems have demonstrated 
an ability to achieve sustained release locoregionally, but 
further improvement is welcomed.40,48,252 Nevertheless, the 
timing of the drug administration has to be shortened.30,48 
Additional modifications were made to the molecules, to 
include targeted therapies, such as the epidermal growth 
factor receptor.45 In another study by Garbuzenko et al51 addi-
tional pump and nonpump suppressors were added to inhaled 
doxorubicin. This concept was based on the observation 
that there are two main mechanisms responsible for cancer 
cell chemotherapy resistance, ie, pump and nonpump.253–255 
Pump resistance is caused by membrane efflux pumps that 
decrease the anticancer drug concentration inside cells. 
Nonpump resistance is primarily attributed to the activation 
of antiapoptotic cellular defense, and Bcl-2 is also a key 
parameter in this defense. Similar to MRP 1, expression of 
Bcl-2 protein increases significantly after treatment with 
anticancer drugs.253,255 a-TEA could be used as a molecule 
additional to the aerosol formulation to augment apoptosis 
and decrease cancer cell proliferation.49,57,239 Nebulizers have 
also demonstrated efficiency for delivery and deposition 
of inhaled chemotherapeutic regimens.30,37,52,53 Additional 
modifications have been shown to improve deposition 
further by modifying respiratory rate and tidal volume.82 
Delivery systems have been evaluated for safety regarding 
environmental release of toxins and it has been found that 
certain systems have the ability to deliver their entire drug 
cargo to patients, without any loss to the environment.30,42 
Drug transporter gene expression appears to be high in the 
lungs.215 However, interaction of these genes with inhaled 
drug formulations, any alterations due to underlying respira-
tory disease, and their role in drug deposition are not fully 
explored.226 The transporters are less likely to influence 
absorption of inhaled drugs than they are to exert an effect 
in the gastrointestinal tract; nevertheless, efflux pumps can 
be exploited to prolong drug retention in situ.226 Trans-
porter properties can be fully exploited if a formulation is 
designed for distribution to specific sites in the respiratory 
tract where they are highly expressed in combination with 
the appropriate drug carrier. In addition to the transporters, 
several other carriers have been investigated in combination 
with chemotherapy agents, either in order to make feasible 
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their administration to the lung parenchyma for toxicity 
reasons, or to add a sustained-release capability to the lung 
formulation.34,39,40,47–51,53,55–60 Transporters could be used in 
addition as a prognostic factor.199 Moreover, regarding car-
riers, liposomes would appear to require dosing three or 
four times a day and would be expected to be well tolerated 
within the lung following repeated dosing. Microspheres and 
lipid-coated nanoparticles could be given once or twice daily, 
depending on particle residence time at the site of action. 
However, issues of particle accumulation within the alveoli 
may be encountered with repeated dosing. Due to the com-
position of lipid-coated nanoparticles in comparison with 
microspheres, there would be less of a concern with toxicity 
using lipid-coated nanoparticles.231 The optimal formulation 
for the clinician would be once-a-day delivery of a chemo-
therapy regimen, with the additional effect of pegylation for 
the “stealth” properties previously mentioned.
Finally, the next step in delivering inhaled chemotherapy 
at home has already been made after proper patient education, 
and the concept is intriguing.56 Monitoring of patients can be 
done using peak flow measurements at home between restag-
ing, and addition of a combination of inhaled bronchodila-
tors and corticosteroids before inhaled chemotherapy could 
help prevent adverse effects, such as bronchoconstriction. 
Addition of N-acetylcysteine could be used as a protective 
measure.93,214 Finally, inhaled chemotherapy regimens when 
administered alone demonstrate fewer systemic cytotoxic 
effects, making the concept of safe inhaled chemotherapy the 
next challenge in the treatment of lung cancer. Nevertheless, 
the safety and efficacy of such formulations have yet to be 
fully and completely evaluated (Table 3).
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